ER positive

About

Biomarker Type: Protein expression

Present: True

Marker: Estrogen receptor (ER)

Unit: status

Equality: =

Value: Positive


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) ER positive Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) ER positive, PR positive Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Sacituzumab govitecan HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib HC
Sensitivity (+) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib HC
Sensitivity (+) ER positive, HER2-positive Invasive Breast Carcinoma Neratinib HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 somatic variants, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 somatic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 amplification, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA amplification Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 somatic variants, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 somatic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 amplification, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-positive Invasive Breast Carcinoma Lapatinib, Letrozole FDA
Sensitivity (+) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Sacituzumab govitecan FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan FDA
Sensitivity (+) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Elacestrant FDA
Sensitivity (+) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Imlunestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Datopotamab deruxtecan FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant FDA